S. Glowienke

发表

Thomas E. Exner, G. Myatt, J. Mestres, 2020, Regulatory toxicology and pharmacology : RTP.

Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines.

K. Cross, A. Czich, A. Lynch, 2022, Regulatory toxicology and pharmacology : RTP.

Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry.

A. Elhajouji, S. Glowienke, Jana Nunić, 2016, Toxicological sciences : an official journal of the Society of Toxicology.

Principles and Procedures for Assessment of Acute Toxicity Incorporating In Silico Methods.

Agnes L. Karmaus, David C. Jones, G. Myatt, 2022, Computational toxicology.

Continuous Flow as Enabling Technology: Synthesis of Heteroaromatic Sulfinates as Bench Stable Cross-Coupling Partners.

J. Sedelmeier, B. Martin, B. Schenkel, 2020, Organic letters.

Use of Less-than-Lifetime (LTL) Durational Limits for Nitrosamines: Case Study of N-Nitrosodiethylamine (NDEA).

K. Cross, G. Johnson, A. Czich, 2021, Regulatory toxicology and pharmacology : RTP.

Induction of gene mutations by 5-(2-chloroethyl)-2'-deoxyuridine (CEDU), an antiviral pyrimidine nucleoside analogue.

F. Staedtler, H. Martus, S. Glowienke, 2004, Mutation research.

Avoidance of the Ames test liability for aryl-amines via computation.

Peter Gedeck, Susanne Glowienke, Lewis Whitehead, 2011, Bioorganic & medicinal chemistry.

Genetic toxicology in silico protocol.

Raymond R Tice, Naomi L Kruhlak, Lidiya Stavitskaya, 2019, Regulatory toxicology and pharmacology : RTP.

Bacterial mutagenicity screening in the pharmaceutical industry.

R. Snyder, B. Mahadevan, S. Sawant, 2013, Mutation research.

In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey.

Nigel Greene, Susanne Glowienke, James S Harvey, 2012, Regulatory toxicology and pharmacology : RTP.

Structure-activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters.

Thomas Allmendinger, Susanne Glowienke, Wilfried Frieauff, 2005, Mutation research.

Considerations when deriving compound-specific limits for extractables and leachables from pharmaceutical products: Four case studies.

Susanne Glowienke, Lee M Nagao, Cheryl L M Stults, 2020, Regulatory toxicology and pharmacology : RTP.

A pharma-wide approach to address the genotoxicity prediction of primary aromatic amines

Mick D. Fellows, Robert A. Jolly, Alexander Amberg, 2018, Computational Toxicology.

In silico toxicology protocols.

Tudor I. Oprea, Naomi L Kruhlak, Lidiya Stavitskaya, 2018, Regulatory toxicology and pharmacology : RTP.

Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtained.

Nigel Greene, Alex Harding, Alexander Amberg, 2016, Regulatory toxicology and pharmacology : RTP.

It's difficult, but important, to make negative predictions.

Nigel Greene, Alexander Amberg, Susanne Glowienke, 2016, Regulatory toxicology and pharmacology : RTP.

Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.

Susanne Glowienke, S. Araya, S. Glowienke, 2015, Regulatory toxicology and pharmacology : RTP.

Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity.

A. Elhajouji, A. Hartmann, S. Glowienke, 2022, Regulatory toxicology and pharmacology : RTP.

Potential impurities in drug substances: Compound‐specific toxicology limits for 20 synthetic reagents and by‐products, and a class‐specific toxicology limit for alkyl bromides

S. Galloway, V. Thybaud, R. Jolly, 2018, Regulatory toxicology and pharmacology : RTP.

Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities.

Scott Boyer, Nigel Greene, Lutz Müller, 2013, Regulatory toxicology and pharmacology : RTP.

Assessing safety of extractables from materials and leachables in pharmaceuticals and biologics - Current challenges and approaches.

Thomas H Broschard, Susanne Glowienke, Uma S Bruen, 2016, Regulatory toxicology and pharmacology : RTP.

Acceptable Intakes (AIs) for 11 Small molecule N-nitrosamines (NAs).

R. Weaver, A. Czich, D. Snodin, 2023, Regulatory toxicology and pharmacology : RTP.

Making reliable negative predictions of human skin sensitisation using an in silico fragmentation approach

Rahul Parakhia, Susanne Glowienke, Phillip Bellion, 2018, Regulatory toxicology and pharmacology : RTP.

Establishing best practise in the application of expert review of mutagenicity under ICH M7.

Lidiya Stavitskaya, Alexander Amberg, Steve Gutsell, 2015, Regulatory toxicology and pharmacology : RTP.

Qualification of impurities based on metabolite data.

W. Muster, Chuang Lu, B. Trela, 2019, Regulatory toxicology and pharmacology : RTP.

Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses

Lidiya Stavitskaya, Raymond Kemper, Glenn J. Myatt, 2018, Regulatory toxicology and pharmacology : RTP.

Calculating Qualified Non-Mutagenic Impurity Levels: Harmonization of Approaches.

J. Bercu, M. Kenyon, M. Powley, 2021, Regulatory toxicology and pharmacology : RTP.

Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.

Lidiya Stavitskaya, Raymond Kemper, Alexander Amberg, 2016, Regulatory toxicology and pharmacology : RTP.

Potential impurities in drug substances: Compound‐specific toxicology limits for 20 synthetic reagents and by‐products, and a class‐specific toxicology limit for alkyl bromides

S. M. Galloway, A. Teasdale, Krista L Dobo, 2018, Regulatory toxicology and pharmacology : RTP.

Bacterial mutagenicity screening in the pharmaceutical industry.

R. Snyder, B. Mahadevan, T. E. Johnson, 2013, Mutation research.